Omega Healthcare Investors (OHI) Financials

$42.20 -0.16 (-0.38%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$42.21 +0.01 (+0.02%)

As of 08/22/2025 07:29 PM Eastern

Annual Income Statements for Omega Healthcare Investors

This table shows Omega Healthcare Investors' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	225	750	100	282	341	159	417	427	242	406
Consolidated Net Income / (Loss)	233	767	105	294	352	164	428	439	249	418
Net Income / (Loss) Continuing Operations	233	767	105	294	352	164	428	439	249	418
Total Pre-Tax Income	235	769	106	297	344	162	416	436	256	421
Total Revenue	744	1,729	963	705	776	688	828	1,005	714	830
Net Interest Income / (Expense)	0.00	-173	-9.52	-201	-209	-223	-98	-109	-116	-65
Total Interest Income	0.00	0.17	0.00	0.00	0.00	0.00	136	124	120	157
Loans and Leases Interest Income	-	-	-	-	-	-	136	124	120	157
Total Interest Expense	0.00	173	9.52	201	209	223	235	233	236	222
Long-Term Debt Interest Expense	-	164	-	201	209	223	235	233	236	222
Total Non-Interest Income	744	1,902	973	906	985	911	926	1,114	830	894
Other Service Charges	78	189	101	113	124	138	1.14	3.09	3.46	6.27
Other Non-Interest Income	666	1,612	808	769	805	754	925	751	826	888
Provision for Credit Losses	-	9.85	-	6.69	0.00	38	78	69	45	-15
Total Non-Interest Expense	332	774	647	402	433	474	304	498	434	429
Other Operating Expenses	46	104	48	64	73	69	77	85	97	103
Depreciation Expense	211	534	288	281	302	330	342	332	320	305
Impairment Charge	18	117	297	57	53	72	45	38	92	24
Restructuring Charge	58	19	-	0.38	5.12	2.02	1.81	42	5.34	12
Other Special Charges	-	-	15	-	-	-	-162	-	-80	-13
Nonoperating Income / (Expense), net	-177	-176	-210	0.35	0.81	-14	-31	-2.39	20	5.08
Income Tax Expense	1.21	2.81	3.25	3.01	2.84	4.93	3.84	4.56	6.26	11
Other Gains / (Losses), net	-	0.88	2.24	0.38	11	6.14	16	7.26	-0.58	7.92
Net Income / (Loss) Attributable to Noncontrolling Interest	8.79	17	4.49	12	11	4.22	12	12	6.62	11
Basic Earnings per Share	$1.30	$3.82	$0.51	$1.41	$1.60	$0.70	$1.76	$1.81	$1.01	$1.57
Weighted Average Basic Shares Outstanding	172.24M	593.14M	197.74M	209.71M	226.81M	231.78M	239.11M	234.27M	245.30M	281.84M
Diluted Earnings per Share	$1.29	$3.80	$0.51	$1.40	$1.58	$0.70	$1.75	$1.80	$1.00	$1.55
Weighted Average Diluted Shares Outstanding	180.51M	403.27M	206.79M	209.71M	226.81M	231.78M	239.11M	234.27M	245.30M	281.84M
Weighted Average Basic & Diluted Shares Outstanding	172.70M	201.64M	206.79M	209.71M	226.81M	231.78M	239.11M	234.27M	245.30M	281.84M
Cash Dividends to Common per Share	$2.18	$2.36	$2.54	$2.64	$2.65	$2.68	$2.68	$2.68	$2.68	$2.68

This table shows Omega Healthcare Investors' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	102	46	36	60	91	55	67	114	112	113	109
Consolidated Net Income / (Loss)	105	47	37	62	94	57	69	117	115	116	112
Net Income / (Loss) Continuing Operations	105	47	37	62	94	57	69	117	115	116	112
Total Pre-Tax Income	102	48	35	62	97	62	72	119	111	119	115
Total Revenue	222	296	160	192	183	179	191	199	221	219	235
Net Interest Income / (Expense)	-27	-28	-30	-30	-28	-28	-22	-16	-15	-12	-9.16
Total Interest Income	31	30	28	29	31	32	36	38	40	43	43
Loans and Leases Interest Income	31	30	28	29	31	32	36	38	40	43	43
Total Interest Expense	58	58	59	59	59	59	58	54	55	55	52
Long-Term Debt Interest Expense	58	58	59	59	59	59	58	54	55	55	52
Total Non-Interest Income	249	325	190	222	211	207	213	215	236	231	244
Other Service Charges	0.24	4.64	0.45	2.63	1.21	-0.83	5.82	0.39	4.60	-4.54	1.49
Net Realized & Unrealized Capital Gains on Investments	41	-	-	-	-	-	-	-	-0.24	-	10
Other Non-Interest Income	208	115	189	219	210	208	207	214	231	235	232
Provision for Credit Losses	4.11	64	-4.06	13	2.73	33	8.47	-14	-9.06	-0.72	5.09
Total Non-Interest Expense	115	182	132	117	89	96	109	97	118	106	118
Other Operating Expenses	22	20	25	26	24	22	25	26	25	26	35
Depreciation Expense	83	84	81	82	81	76	75	74	77	79	80
Impairment Charge	10	17	39	21	28	3.95	5.29	8.18	8.62	1.74	1.24
Restructuring Charge	0.19	36	0.64	0.42	0.12	4.16	2.60	1.78	6.44	0.80	1.46
Nonoperating Income / (Expense), net	-0.55	-1.37	2.71	0.00	5.40	12	-1.28	3.15	-1.18	4.39	3.05
Income Tax Expense	1.19	1.03	-1.29	1.63	1.76	4.16	2.58	1.98	3.32	2.98	3.61
Other Gains / (Losses), net	4.12	-0.26	0.83	1.07	-1.35	-1.14	0.10	0.14	6.88	0.80	1.08
Net Income / (Loss) Attributable to Noncontrolling Interest	2.79	1.13	0.90	1.67	2.53	1.52	1.99	3.22	3.15	3.12	3.03
Basic Earnings per Share	$0.44	$0.20	$0.15	$0.25	$0.37	$0.24	$0.27	$0.46	$0.43	$0.41	$0.34
Weighted Average Basic Shares Outstanding	234.18M	234.27M	234.35M	244.87M	244.99M	245.30M	247.10M	257.84M	269.95M	281.84M	289.40M
Diluted Earnings per Share	$0.43	$0.20	$0.15	$0.25	$0.37	$0.23	$0.27	$0.45	$0.42	$0.41	$0.33
Weighted Average Diluted Shares Outstanding	234.18M	234.27M	234.35M	244.87M	244.99M	245.30M	247.10M	257.84M	269.95M	281.84M	289.40M
Weighted Average Basic & Diluted Shares Outstanding	234.18M	234.27M	234.35M	244.87M	244.99M	245.30M	247.10M	257.84M	269.95M	281.84M	289.40M
Cash Dividends to Common per Share	$0.67	-	$0.67	$0.67	$0.67	-	$0.67	$0.67	$0.67	-	$0.67

This table details how cash moves in and out of Omega Healthcare Investors' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-14	87	-10	-85	22	134	-143	276	144	104
Net Cash From Operating Activities	-17	625	578	499	554	708	722	626	618	749
Net Cash From Continuing Operating Activities	449	625	578	499	554	708	723	626	618	749
Net Income / (Loss) Continuing Operations	0.00	383	105	294	352	164	428	439	249	418
Consolidated Net Income / (Loss)	-	383	105	294	352	164	428	439	249	418
Provision For Loan Losses	7.87	9.85	15	0.00	11	185	117	193	65	-11
Depreciation Expense	211	267	288	281	302	330	342	332	320	305
Amortization Expense	22	-2.53	7.80	-1.75	3.66	-2.58	34	7.68	4.74	10
Non-Cash Adjustments to Reconcile Net Income	209	-32	227	-7.73	-37	35	-105	-303	36	38
Changes in Operating Assets and Liabilities, net	0.15	-1.03	-64	-66	-77	-1.87	-93	-44	-57	-10
Net Cash From Investing Activities	-397	-1,114	-285	-173	-379	-89	-524	443	-0.77	-671
Net Cash From Continuing Investing Activities	-397	-1,114	-285	-173	-379	-89	-524	443	-0.77	-671
Purchase of Property, Leasehold Improvements and Equipment	-191	-109	-124	-169	-53	-106	-45	-47	-83	-107
Purchase of Investment Securities	-380	-1,332	-566	-556	-603	-344	-867	-602	-684	-871
Divestitures	85	1.32	15	5.47	9.08	6.29	18	3.33	8.81	1.02
Sale and/or Maturity of Investments	89	326	391	547	459	357	476	1,105	757	306
Net Cash From Financing Activities	-65	576	-304	-411	-154	-486	-341	-789	-473	26
Net Cash From Continuing Financing Activities	-65	576	-304	-411	-154	-486	-341	-789	-473	26
Issuance of Debt	3,664	2,352	3,034	1,291	2,002	1,852	2,275	597	507	658
Issuance of Common Equity	590	260	59	122	516	152	274	8.11	336	1,236
Repayment of Debt	-3,923	-1,537	-2,869	-1,270	-2,086	-1,856	-2,227	-590	-739	-1,152
Repurchase of Common Equity	-	-	-	-	-	0.00	0.00	-142	0.00	0.00
Payment of Dividends	-370	-453	-503	-529	-585	-612	-663	-653	-670	-715
Other Financing Activities, Net	-27	-45	-25	-25	0.00	-21	-0.08	-9.62	92	-0.14
Effect of Exchange Rate Changes	-	-	0.57	-0.59	-	0.53	-	-	0.43	-0.58

This table details how cash moves in and out of Omega Healthcare Investors' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	-30	162	-52	108	201	-113	-82	-324	321	188	-145
Net Cash From Operating Activities	167	154	111	170	171	165	151	184	185	229	182
Net Cash From Continuing Operating Activities	167	154	111	170	171	165	151	184	185	229	182
Net Income / (Loss) Continuing Operations	105	47	37	62	94	57	69	117	115	116	112
Consolidated Net Income / (Loss)	105	47	37	62	94	57	69	117	115	116	112
Provision For Loan Losses	18	160	8.44	14	9.97	33	8.47	-14	-7.93	2.32	5.09
Depreciation Expense	83	84	81	82	81	76	75	74	77	79	80
Amortization Expense	2.65	1.15	-2.87	2.61	1.35	3.65	4.43	3.04	0.78	2.21	1.38
Non-Cash Adjustments to Reconcile Net Income	-28	-156	32	15	-7.88	-2.48	13	2.19	9.66	13	15
Changes in Operating Assets and Liabilities, net	-14	17	-44	-4.58	-7.12	-1.30	-19	1.73	-9.78	16	-31
Net Cash From Investing Activities	-4.75	170	2.66	-187	73	111	-47	-209	-133	-282	19
Net Cash From Continuing Investing Activities	-4.75	170	2.66	-187	73	111	-47	-209	-133	-282	19
Purchase of Property, Leasehold Improvements and Equipment	-3.48	-9.50	-5.34	-7.85	-10	-59	-21	-35	-25	-25	-35
Acquisitions	-	-	0.00	-8.20	-	-	-	-	-	-	-30
Purchase of Investment Securities	-139	-146	-58	-280	-128	-218	-61	-252	-182	-377	-100
Divestitures	0.16	1.99	0.38	0.75	1.88	5.79	0.94	0.31	1.59	-1.82	1.16
Sale and/or Maturity of Investments	149	328	70	115	213	360	34	77	72	122	184
Net Cash From Financing Activities	-191	-162	-166	125	-42	-390	-186	-299	268	243	-348
Net Cash From Continuing Financing Activities	-191	-162	-166	125	-42	-390	-186	-299	268	243	-348
Issuance of Common Equity	2.33	2.29	1.99	200	126	8.66	32	243	526	434	261
Repayment of Debt	-113	-1.90	-1.92	-84	-425	-228	-43	-849	-258	-2.63	-401
Payment of Dividends	-162	-162	-167	-163	-170	-170	-175	-172	-180	-188	-208
Other Net Changes in Cash	-	0.33	0.28	0.21	-0.35	-	-	-	-	-	1.82

This table presents Omega Healthcare Investors' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	7,990	8,949	8,773	17,182	9,796	9,497	9,638	9,405	9,117	9,898
Cash and Due from Banks	5.42	94	86	21	24	164	21	297	443	518
Restricted Cash	15	-	11	2.74	9.26	4.02	3.88	3.54	1.92	30
Trading Account Securities	-	49	37	62	200	201	195	179	188	89
Loans and Leases, Net of Allowance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Premises and Equipment, Net	5,725	6,326	6,279	-3,125	7,199	6,705	6,847	6,537	5,903	6,339
Goodwill	646	643	645	1,288	644	652	651	643	644	644
Other Assets	920	1,198	1,045	1,392	946	887	1,921	1,745	1,938	2,278
Total Liabilities & Shareholders' Equity	7,990	8,949	8,773	17,182	9,796	9,497	9,638	9,405	9,117	9,898
Total Liabilities	3,889	4,737	4,885	4,667	5,460	5,461	5,530	5,602	5,355	5,167
Short-Term Debt	230	190	290	313	125	101	0.00	19	20	0.00
Long-Term Debt	3,310	4,177	4,282	4,327	5,011	5,068	5,254	5,268	5,047	4,839
Other Long-Term Liabilities	15	370	18	27	323	292	277	315	288	328
Total Equity & Noncontrolling Interests	4,101	4,212	3,888	3,764	4,337	4,037	4,108	3,803	3,762	4,731
Total Preferred & Common Equity	3,738	3,859	3,555	3,444	4,135	3,842	3,907	3,609	3,575	4,537
Preferred Stock	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	3,738	3,859	3,555	3,444	4,135	3,842	3,907	3,609	3,575	4,537
Common Stock	4,628	4,881	4,956	5,095	6,015	6,176	6,451	6,338	6,696	7,944
Retained Earnings	-882	-968	-1,371	-1,609	-1,840	-2,321	-2,542	-2,749	-3,150	-3,430
Accumulated Other Comprehensive Income / (Loss)	-8.71	-54	-30	-42	-40	-13	-2.20	20	29	23
Noncontrolling Interest	363	353	333	320	201	195	201	194	188	194

This table presents Omega Healthcare Investors' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025
Total Assets	9,476	9,290	9,404	9,425	9,012	8,849	9,572	9,706
Cash and Due from Banks	135	245	351	555	362	35	342	368
Restricted Cash	3.32	3.34	5.82	3.21	1.25	3.94	18	36
Trading Account Securities	177	181	192	188	186	185	93	89
Loans and Leases, Net of Allowance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Premises and Equipment, Net	6,462	6,438	6,489	6,193	5,834	5,877	6,292	6,333
Goodwill	649	644	644	643	644	644	645	644
Other Assets	1,380	1,779	1,723	1,844	1,985	2,103	2,183	2,236
Total Liabilities & Shareholders' Equity	9,476	9,290	9,404	9,425	9,012	8,849	9,572	9,706
Total Liabilities	5,580	5,605	5,591	5,568	5,311	4,948	5,172	4,774
Short-Term Debt	18	20	20	20	20	70	0.00	0.00
Long-Term Debt	5,267	5,268	5,267	5,272	5,008	4,590	4,858	4,446
Other Long-Term Liabilities	295	317	305	277	283	287	313	327
Total Equity & Noncontrolling Interests	3,895	3,686	3,813	3,857	3,701	3,901	4,400	4,932
Total Preferred & Common Equity	3,698	3,497	3,624	3,669	3,514	3,711	4,208	4,741
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	3,698	3,497	3,624	3,669	3,514	3,711	4,208	4,741
Common Stock	6,329	6,346	6,550	6,682	6,730	6,977	7,507	8,208
Retained Earnings	-2,637	-2,870	-2,968	-3,041	-3,248	-3,300	-3,362	-3,510
Accumulated Other Comprehensive Income / (Loss)	6.24	22	41	28	32	34	63	43
Noncontrolling Interest	197	189	188	188	187	190	192	191

This table displays calculated financial ratios and metrics derived from Omega Healthcare Investors' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	47.31%	132.45%	-44.28%	-26.80%	10.04%	-11.31%	20.28%	21.43%	-28.93%	16.17%
EBITDA Growth	36.70%	87.72%	-49.42%	-5.85%	12.62%	-22.28%	63.07%	-5.24%	-28.04%	30.44%
EBIT Growth	19.10%	129.60%	-66.53%	-6.30%	15.82%	-48.53%	152.70%	-1.70%	-46.22%	76.26%
NOPAT Growth	18.49%	129.95%	-67.44%	-4.31%	16.04%	-49.68%	158.61%	-1.98%	-46.98%	76.02%
Net Income Growth	5.41%	228.63%	-86.32%	180.13%	19.76%	-53.53%	161.89%	2.46%	-43.31%	67.93%
EPS Growth	-25.86%	194.57%	-86.58%	174.51%	12.86%	-55.70%	150.00%	2.86%	-44.44%	55.00%
Operating Cash Flow Growth	-105.10%	3,729.45%	-7.50%	-13.59%	10.89%	27.90%	1.96%	-13.35%	-1.28%	21.32%
Free Cash Flow Firm Growth	-3,038.15%	100.08%	14,691.21%	-2,077.62%	195.49%	-94.54%	-34.53%	146.01%	-30.47%	-168.32%
Invested Capital Growth	102.15%	12.28%	-1.38%	102.76%	-44.78%	-2.82%	1.69%	-2.90%	-2.87%	8.38%
Revenue Q/Q Growth	6.26%	99.13%	-45.18%	-9.22%	5.86%	-22.01%	-1.81%	35.93%	51.46%	2.46%
EBITDA Q/Q Growth	7.55%	61.78%	-44.33%	-7.94%	9.68%	-5.62%	-11.22%	1.78%	-0.85%	6.61%
EBIT Q/Q Growth	0.51%	97.01%	-60.86%	-13.08%	15.02%	-14.14%	-19.81%	3.82%	0.33%	11.79%
NOPAT Q/Q Growth	-0.68%	96.95%	-60.42%	-0.25%	-1.41%	-14.87%	-8.67%	3.71%	-0.85%	12.63%
Net Income Q/Q Growth	2.89%	141.85%	-81.03%	-0.09%	-1.06%	1.19%	-6.31%	2.92%	4.11%	16.75%
EPS Q/Q Growth	-8.51%	140.51%	-81.32%	-0.71%	-2.47%	1.45%	-8.38%	4.65%	3.09%	13.14%
Operating Cash Flow Q/Q Growth	-104.30%	260.30%	-47.55%	0.05%	-0.52%	7.49%	-5.35%	-0.45%	1.86%	9.34%
Free Cash Flow Firm Q/Q Growth	17.61%	-98.39%	-46.60%	-1,756.86%	48,424.16%	311.04%	234.99%	-5.76%	86.05%	-234.25%
Invested Capital Q/Q Growth	-8.05%	-0.35%	-1.48%	104.85%	8.85%	1.04%	-1.56%	-0.98%	-3.49%	3.36%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	86.60%	69.93%	63.48%	81.66%	83.57%	73.23%	99.28%	77.48%	78.44%	88.08%
EBIT Margin	55.31%	54.63%	32.81%	42.01%	44.22%	25.66%	53.90%	43.64%	33.02%	50.10%
Profit (Net Income) Margin	31.38%	44.36%	10.89%	41.68%	45.37%	23.77%	51.75%	43.67%	34.84%	50.36%
Tax Burden Percent	99.48%	99.75%	99.05%	99.11%	102.36%	100.75%	102.94%	100.62%	97.33%	99.30%
Interest Burden Percent	57.03%	81.40%	33.51%	100.12%	100.24%	91.95%	93.27%	99.46%	108.40%	101.22%
Effective Tax Rate	0.52%	0.37%	3.07%	1.02%	0.83%	3.03%	0.92%	1.05%	2.45%	2.58%
Return on Invested Capital (ROIC)	7.17%	11.60%	3.60%	2.29%	2.56%	1.83%	4.77%	4.70%	2.57%	4.40%
ROIC Less NNEP Spread (ROIC-NNEP)	1.22%	7.20%	-0.91%	2.30%	2.68%	1.68%	4.49%	4.80%	2.93%	4.66%
Return on Net Nonoperating Assets (RNNOA)	1.32%	6.85%	-1.01%	5.39%	6.13%	2.07%	5.75%	6.39%	4.01%	5.44%
Return on Equity (ROE)	8.48%	18.45%	2.59%	7.68%	8.69%	3.91%	10.52%	11.09%	6.58%	9.84%
Cash Return on Invested Capital (CROIC)	-60.45%	0.04%	4.99%	-65.59%	60.25%	4.69%	3.09%	7.65%	5.48%	-3.64%
Operating Return on Assets (OROA)	6.91%	11.15%	3.57%	2.28%	2.54%	1.83%	4.66%	4.61%	2.55%	4.37%
Return on Assets (ROA)	3.92%	9.05%	1.18%	2.26%	2.61%	1.70%	4.48%	4.61%	2.69%	4.39%
Return on Common Equity (ROCE)	7.92%	16.86%	2.37%	7.02%	8.13%	3.72%	10.01%	10.54%	6.25%	9.40%
Return on Equity Simple (ROE_SIMPLE)	6.24%	19.87%	2.95%	8.53%	8.51%	4.26%	10.96%	12.16%	6.96%	9.21%
Net Operating Profit after Tax (NOPAT)	409	941	306	293	340	171	443	434	230	405
NOPAT Margin	55.02%	54.43%	31.81%	41.58%	43.85%	24.88%	53.49%	43.18%	32.21%	48.81%
Net Nonoperating Expense Percent (NNEP)	5.94%	4.40%	4.51%	-0.01%	-0.13%	0.15%	0.28%	-0.09%	-0.36%	-0.26%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	44.69%	44.80%	67.19%	57.04%	55.78%	68.82%	36.70%	49.53%	60.74%	51.77%
Earnings before Interest and Taxes (EBIT)	411	944	316	296	343	177	446	439	236	416
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	644	1,209	611	576	648	504	822	779	560	731
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.86	0.83	0.87	1.28	1.50	1.56	1.42	1.51	1.91	2.21
Price to Tangible Book Value (P/TBV)	1.04	1.00	1.07	2.04	1.77	1.88	1.70	1.83	2.33	2.58
Price to Revenue (P/Rev)	4.31	1.86	3.22	6.25	7.98	8.71	6.70	5.41	9.55	12.10
Price to Earnings (P/E)	14.27	4.28	30.91	15.65	18.14	37.60	13.31	12.73	28.16	24.70
Dividend Yield	12.73%	14.35%	16.21%	12.03%	9.36%	10.16%	11.55%	11.55%	9.63%	7.21%
Earnings Yield	7.01%	23.36%	3.23%	6.39%	5.51%	2.66%	7.51%	7.85%	3.55%	4.05%
Enterprise Value to Invested Capital (EV/IC)	0.93	0.91	0.94	0.54	1.21	1.22	1.17	1.17	1.32	1.52
Enterprise Value to Revenue (EV/Rev)	9.53	4.53	8.22	13.25	14.81	16.26	13.26	10.56	16.28	17.50
Enterprise Value to EBITDA (EV/EBITDA)	11.00	6.48	12.94	16.23	17.72	22.20	13.36	13.63	20.76	19.87
Enterprise Value to EBIT (EV/EBIT)	17.23	8.30	25.03	31.54	33.50	63.37	24.60	24.21	49.32	34.93
Enterprise Value to NOPAT (EV/NOPAT)	17.32	8.33	25.83	31.87	33.78	65.35	24.79	24.46	50.55	35.86
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	12.54	13.69	18.71	20.75	15.80	15.20	16.97	18.83	19.38
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	2,728.31	18.63	0.00	1.43	25.54	38.27	15.05	23.71	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.86	1.04	1.18	1.23	1.18	1.28	1.28	1.39	1.35	1.02
Long-Term Debt to Equity	0.81	0.99	1.10	1.15	1.16	1.26	1.28	1.39	1.34	1.02
Financial Leverage	1.08	0.95	1.10	2.35	2.29	1.23	1.28	1.33	1.37	1.17
Leverage Ratio	2.16	2.04	2.19	3.39	3.33	2.30	2.35	2.41	2.45	2.24
Compound Leverage Factor	1.23	1.66	0.73	3.40	3.34	2.12	2.19	2.39	2.65	2.27
Debt to Total Capital	46.33%	50.90%	54.04%	55.21%	54.22%	56.15%	56.12%	58.16%	57.39%	50.56%
Short-Term Debt to Total Capital	3.01%	2.21%	3.43%	3.72%	1.32%	1.10%	0.00%	0.21%	0.23%	0.00%
Long-Term Debt to Total Capital	43.32%	48.69%	50.61%	51.49%	52.90%	55.05%	56.12%	57.95%	57.16%	50.56%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	4.75%	4.12%	3.94%	3.81%	2.12%	2.12%	2.15%	2.13%	2.13%	2.03%
Common Equity to Total Capital	48.92%	44.98%	42.02%	40.98%	43.66%	41.73%	41.73%	39.71%	40.48%	47.41%
Debt to EBITDA	5.50	3.61	7.48	8.06	7.92	10.26	6.39	6.79	9.04	6.62
Net Debt to EBITDA	5.47	3.54	7.32	8.02	7.87	9.93	6.36	6.40	8.25	5.87
Long-Term Debt to EBITDA	5.14	3.46	7.00	7.52	7.73	10.06	6.39	6.77	9.01	6.62
Debt to NOPAT	8.65	4.64	14.92	15.83	15.10	30.20	11.87	12.18	22.03	11.95
Net Debt to NOPAT	8.60	4.54	14.61	15.75	15.00	29.22	11.81	11.49	20.09	10.59
Long-Term Debt to NOPAT	8.09	4.44	13.98	14.76	14.73	29.61	11.87	12.14	21.94	11.95
Noncontrolling Interest Sharing Ratio	6.60%	8.61%	8.47%	8.54%	6.43%	4.73%	4.86%	5.00%	5.04%	4.50%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-3,452	2.87	425	-8,401	8,022	438	287	706	491	-335
Operating Cash Flow to CapEx	-9.03%	570.81%	464.35%	295.02%	1,046.94%	667.01%	1,606.60%	1,325.10%	748.72%	702.13%
Free Cash Flow to Firm to Interest Expense	0.00	0.02	44.64	-41.71	38.44	1.96	1.22	3.03	2.08	-1.51
Operating Cash Flow to Interest Expense	0.00	3.60	60.73	2.48	2.65	3.17	3.08	2.68	2.62	3.38
Operating Cash Flow Less CapEx to Interest Expense	0.00	2.97	47.65	1.64	2.40	2.70	2.89	2.48	2.27	2.90
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.12	0.20	0.11	0.05	0.06	0.07	0.09	0.11	0.08	0.09
Fixed Asset Turnover	0.18	0.29	0.15	0.00	0.00	0.10	0.12	0.15	0.11	0.14
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	7,641	8,579	8,460	17,155	9,473	9,206	9,362	9,090	8,830	9,570
Invested Capital Turnover	0.13	0.21	0.11	0.06	0.06	0.07	0.09	0.11	0.08	0.09
Increase / (Decrease) in Invested Capital	3,861	938	-118	8,694	-7,682	-267	156	-272	-261	740
Enterprise Value (EV)	7,086	7,836	7,913	9,342	11,491	11,187	10,976	10,616	11,630	14,521
Market Capitalization	3,203	3,209	3,104	4,405	6,188	5,990	5,546	5,436	6,820	10,037
Book Value per Share	$19.98	$19.77	$17.95	$17.16	$18.93	$16.92	$16.35	$15.41	$14.59	$16.81
Tangible Book Value per Share	$16.53	$16.48	$14.69	$10.75	$15.98	$14.05	$13.62	$12.67	$11.96	$14.42
Total Capital	7,641	8,579	8,460	8,405	9,473	9,206	9,362	9,090	8,830	9,570
Total Debt	3,540	4,367	4,572	4,640	5,136	5,169	5,254	5,287	5,067	4,839
Total Long-Term Debt	3,310	4,177	4,282	4,327	5,011	5,068	5,254	5,268	5,047	4,839
Net Debt	3,520	4,273	4,475	4,617	5,103	5,002	5,229	4,986	4,623	4,290
Capital Expenditures (CapEx)	191	109	124	169	53	106	45	47	83	107
Net Nonoperating Expense (NNE)	176	174	201	-0.72	-12	7.64	14	-4.90	-19	-13
Net Nonoperating Obligations (NNO)	3,540	4,367	4,572	13,390	5,136	5,169	5,254	5,287	5,067	4,839
Total Depreciation and Amortization (D&A)	233	265	295	280	305	327	376	340	324	315
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.30	$1.91	$0.51	$1.41	$1.60	$0.70	$1.76	$1.81	$1.01	$1.57
Adjusted Weighted Average Basic Shares Outstanding	172.24M	191.78M	197.74M	618.32M	213.40M	231.78M	239.11M	234.27M	245.30M	281.84M
Adjusted Diluted Earnings per Share	$1.29	$1.90	$0.51	$1.40	$1.58	$0.70	$1.75	$1.80	$1.00	$1.55
Adjusted Weighted Average Diluted Shares Outstanding	180.51M	201.64M	206.79M	419.42M	222.13M	231.78M	239.11M	234.27M	245.30M	281.84M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$1.60	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	188.13M	196.74M	198.59M	209.71M	226.81M	231.78M	239.11M	234.27M	245.30M	281.84M
Normalized Net Operating Profit after Tax (NOPAT)	484	1,077	609	350	398	243	329	514	247	427
Normalized NOPAT Margin	65.08%	62.30%	63.19%	49.64%	51.30%	35.38%	39.71%	51.10%	34.62%	51.42%
Pre Tax Income Margin	31.54%	44.47%	11.00%	42.06%	44.32%	23.59%	50.27%	43.40%	35.79%	50.71%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	5.44	33.21	1.47	1.64	0.79	1.90	1.88	1.00	1.87
NOPAT to Interest Expense	0.00	5.42	32.20	1.46	1.63	0.77	1.89	1.86	0.98	1.83
EBIT Less CapEx to Interest Expense	0.00	4.81	20.14	0.63	1.39	0.32	1.71	1.68	0.65	1.39
NOPAT Less CapEx to Interest Expense	0.00	4.79	19.12	0.62	1.38	0.29	1.70	1.66	0.63	1.35
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	158.53%	59.10%	479.08%	179.90%	166.34%	374.40%	154.77%	148.89%	269.40%	171.06%
Augmented Payout Ratio	158.53%	59.10%	479.08%	179.90%	166.34%	374.40%	154.77%	181.31%	269.40%	171.06%

This table displays calculated financial ratios and metrics derived from Omega Healthcare Investors' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-20.35%	870.70%	-47.62%	5.81%	-17.50%	-39.61%	19.48%	3.29%	20.65%	22.46%	27.43%
EBITDA Growth	-19.10%	11.28%	-60.54%	-17.00%	-7.60%	-3.57%	37.86%	31.59%	9.66%	50.69%	30.84%
EBIT Growth	-28.52%	48.59%	-83.60%	-31.98%	-10.79%	1.57%	128.42%	86.49%	22.84%	127.91%	64.43%
NOPAT Growth	-28.87%	47.25%	-82.89%	-32.94%	-11.37%	-3.20%	112.31%	88.32%	21.38%	138.22%	65.19%
Net Income Growth	-26.44%	36.42%	-81.12%	-33.07%	-10.62%	21.02%	88.21%	90.31%	22.37%	106.05%	61.60%
EPS Growth	-25.86%	66.67%	-81.01%	-34.21%	-13.95%	15.00%	80.00%	80.00%	13.51%	78.26%	22.22%
Operating Cash Flow Growth	-10.91%	-1.82%	-15.77%	-1.51%	2.50%	7.35%	36.02%	8.06%	8.11%	38.79%	20.12%
Free Cash Flow Firm Growth	268.35%	359.91%	10,312.00%	-33.20%	-71.84%	-3.96%	-61.45%	205.10%	-100.59%	-304.61%	-274.57%
Invested Capital Growth	-3.47%	-2.90%	-8.04%	-1.66%	-0.34%	-2.87%	-2.73%	-5.92%	1.20%	8.38%	7.44%
Revenue Q/Q Growth	22.13%	33.33%	350.25%	20.53%	-4.77%	-2.40%	-4.22%	4.21%	11.23%	-0.93%	7.09%
EBITDA Q/Q Growth	6.40%	-28.61%	-17.82%	32.97%	18.44%	-25.50%	1.56%	26.92%	-1.29%	2.38%	-1.17%
EBIT Q/Q Growth	12.53%	-51.93%	-35.15%	93.95%	47.57%	-45.28%	3.81%	58.34%	-2.80%	1.53%	-2.37%
NOPAT Q/Q Growth	12.59%	-52.41%	-31.27%	82.09%	48.79%	-48.02%	7.30%	61.51%	-4.09%	2.02%	-3.01%
Net Income Q/Q Growth	14.31%	-55.55%	-21.11%	66.97%	52.64%	-39.81%	22.69%	68.83%	-1.85%	1.35%	-3.78%
EPS Q/Q Growth	13.16%	-53.49%	-25.00%	66.67%	48.00%	-37.84%	17.39%	66.67%	-6.67%	-2.38%	-19.51%
Operating Cash Flow Q/Q Growth	-3.55%	-7.89%	-27.54%	53.00%	0.38%	-3.53%	-8.19%	21.54%	0.42%	23.84%	-20.53%
Free Cash Flow Firm Q/Q Growth	34.94%	-25.90%	155.62%	-73.87%	-43.11%	152.69%	-3.35%	106.83%	-100.11%	-87,442.62%	13.87%
Invested Capital Q/Q Growth	-0.78%	-0.98%	-1.28%	1.40%	0.54%	-3.49%	-1.14%	-1.92%	8.15%	3.36%	-2.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	84.66%	45.33%	69.10%	76.23%	94.82%	72.38%	79.73%	97.12%	86.18%	89.06%	82.19%
EBIT Margin	46.23%	16.67%	20.05%	32.26%	49.99%	28.03%	38.33%	58.24%	50.90%	52.16%	47.55%
Profit (Net Income) Margin	47.30%	15.77%	23.08%	31.97%	51.24%	31.60%	36.35%	58.90%	51.97%	53.17%	47.77%
Tax Burden Percent	102.86%	97.32%	106.11%	99.10%	96.80%	91.43%	96.54%	98.45%	103.20%	98.16%	97.79%
Interest Burden Percent	99.46%	97.23%	108.48%	100.00%	105.90%	123.32%	98.25%	102.72%	98.95%	103.84%	102.73%
Effective Tax Rate	1.17%	2.14%	-3.72%	2.62%	1.81%	6.73%	3.59%	1.67%	2.98%	2.51%	3.15%
Return on Invested Capital (ROIC)	3.61%	1.78%	1.11%	1.75%	2.53%	2.08%	3.20%	5.01%	4.34%	4.59%	4.48%
ROIC Less NNEP Spread (ROIC-NNEP)	3.68%	1.75%	1.18%	1.77%	2.60%	2.27%	3.17%	5.07%	4.46%	4.69%	4.56%
Return on Net Nonoperating Assets (RNNOA)	4.78%	2.33%	1.64%	2.42%	3.55%	3.11%	4.43%	6.54%	5.48%	5.47%	5.01%
Return on Equity (ROE)	8.40%	4.10%	2.75%	4.16%	6.07%	5.19%	7.63%	11.55%	9.82%	10.05%	9.48%
Cash Return on Invested Capital (CROIC)	8.01%	7.65%	11.30%	4.33%	2.88%	5.48%	6.01%	9.95%	2.71%	-3.64%	-2.23%
Operating Return on Assets (OROA)	3.55%	1.76%	1.04%	1.74%	2.49%	2.16%	3.21%	4.93%	4.34%	4.55%	4.47%
Return on Assets (ROA)	3.63%	1.66%	1.20%	1.72%	2.56%	2.44%	3.04%	4.98%	4.43%	4.64%	4.49%
Return on Common Equity (ROCE)	7.98%	3.90%	2.61%	3.96%	5.77%	4.93%	7.24%	10.98%	9.37%	9.60%	9.07%
Return on Equity Simple (ROE_SIMPLE)	11.53%	0.00%	8.02%	6.90%	6.51%	0.00%	8.01%	9.08%	8.50%	0.00%	9.71%
Net Operating Profit after Tax (NOPAT)	101	48	33	60	90	47	70	114	109	111	108
NOPAT Margin	45.69%	16.31%	20.79%	31.41%	49.08%	26.14%	36.95%	57.27%	49.38%	50.85%	46.05%
Net Nonoperating Expense Percent (NNEP)	-0.07%	0.03%	-0.07%	-0.02%	-0.07%	-0.19%	0.02%	-0.07%	-0.11%	-0.10%	-0.09%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	51.92%	61.62%	82.49%	61.00%	48.52%	53.57%	57.23%	48.89%	53.20%	48.17%	50.28%
Earnings before Interest and Taxes (EBIT)	103	49	32	62	92	50	73	116	113	114	112
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	188	134	110	147	174	129	152	193	191	195	193
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.57	1.51	1.61	1.79	2.04	1.91	2.12	2.24	2.49	2.21	2.26
Price to Tangible Book Value (P/TBV)	1.91	1.83	1.98	2.17	2.47	2.33	2.60	2.71	2.95	2.58	2.62
Price to Revenue (P/Rev)	7.86	5.41	11.29	12.70	15.85	9.55	9.74	10.77	12.96	12.10	12.19
Price to Earnings (P/E)	14.01	12.73	20.66	26.60	32.11	28.16	27.26	25.38	30.16	24.70	23.96
Dividend Yield	10.80%	11.55%	11.12%	9.69%	8.78%	9.63%	8.80%	7.96%	6.58%	7.21%	7.04%
Earnings Yield	7.14%	7.85%	4.84%	3.76%	3.11%	3.55%	3.67%	3.94%	3.32%	4.05%	4.17%
Enterprise Value to Invested Capital (EV/IC)	1.22	1.17	1.21	1.27	1.35	1.32	1.41	1.53	1.64	1.52	1.60
Enterprise Value to Revenue (EV/Rev)	15.09	10.56	21.75	22.73	26.29	16.28	16.08	17.00	18.75	17.50	17.00
Enterprise Value to EBITDA (EV/EBITDA)	14.58	13.63	17.84	20.02	21.94	20.76	19.78	19.63	22.15	19.87	19.28
Enterprise Value to EBIT (EV/EBIT)	26.41	24.21	39.49	47.13	52.73	49.32	41.42	37.40	40.84	34.93	32.58
Enterprise Value to NOPAT (EV/NOPAT)	26.66	24.46	39.78	47.62	53.42	50.55	42.90	38.56	42.23	35.86	33.44
Enterprise Value to Operating Cash Flow (EV/OCF)	17.74	16.97	17.97	19.26	20.44	18.83	18.71	19.55	22.15	19.38	19.19
Enterprise Value to Free Cash Flow (EV/FCFF)	14.90	15.05	10.28	29.23	47.01	23.71	23.15	14.94	60.82	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.36	1.39	1.43	1.39	1.37	1.35	1.36	1.19	1.10	1.02	0.90
Long-Term Debt to Equity	1.35	1.39	1.43	1.38	1.37	1.34	1.35	1.18	1.10	1.02	0.90
Financial Leverage	1.30	1.33	1.40	1.37	1.36	1.37	1.40	1.29	1.23	1.17	1.10
Leverage Ratio	2.37	2.41	2.47	2.44	2.44	2.45	2.48	2.37	2.30	2.24	2.17
Compound Leverage Factor	2.35	2.34	2.68	2.44	2.58	3.02	2.43	2.43	2.28	2.32	2.23
Debt to Total Capital	57.57%	58.16%	58.93%	58.10%	57.84%	57.39%	57.60%	54.44%	52.47%	50.56%	47.41%
Short-Term Debt to Total Capital	0.19%	0.21%	0.22%	0.22%	0.21%	0.23%	0.23%	0.82%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	57.37%	57.95%	58.71%	57.88%	57.62%	57.16%	57.37%	53.62%	52.47%	50.56%	47.41%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	2.15%	2.13%	2.10%	2.07%	2.06%	2.13%	2.14%	2.22%	2.08%	2.03%	2.04%
Common Equity to Total Capital	40.28%	39.71%	38.97%	39.83%	40.10%	40.48%	40.26%	43.35%	45.45%	47.41%	50.55%
Debt to EBITDA	6.91	6.79	8.68	9.13	9.36	9.04	8.08	6.97	7.09	6.62	5.73
Net Debt to EBITDA	6.73	6.40	8.27	8.51	8.38	8.25	7.50	6.91	6.56	5.87	5.21
Long-Term Debt to EBITDA	6.88	6.77	8.65	9.09	9.33	9.01	8.05	6.87	7.09	6.62	5.73
Debt to NOPAT	12.63	12.18	19.35	21.70	22.80	22.03	17.52	13.69	13.51	11.95	9.93
Net Debt to NOPAT	12.30	11.49	18.44	20.24	20.40	20.09	16.26	13.58	12.51	10.59	9.03
Long-Term Debt to NOPAT	12.59	12.14	19.28	21.62	22.72	21.94	17.45	13.49	13.51	11.95	9.93
Noncontrolling Interest Sharing Ratio	4.90%	5.00%	5.13%	5.01%	4.98%	5.04%	5.08%	4.90%	4.61%	4.50%	4.38%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	432	320	818	214	122	307	315	652	-0.72	-629	-542
Operating Cash Flow to CapEx	4,790.38%	1,617.71%	2,085.39%	2,170.12%	1,690.92%	278.68%	706.27%	530.37%	727.58%	909.79%	516.12%
Free Cash Flow to Firm to Interest Expense	7.41	5.47	13.97	3.64	2.07	5.17	5.45	12.08	-0.01	-11.38	-10.36
Operating Cash Flow to Interest Expense	2.87	2.63	1.90	2.90	2.91	2.78	2.62	3.41	3.38	4.15	3.48
Operating Cash Flow Less CapEx to Interest Expense	2.81	2.47	1.81	2.77	2.74	1.78	2.25	2.77	2.92	3.69	2.81
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.08	0.11	0.05	0.05	0.05	0.08	0.08	0.08	0.09	0.09	0.09
Fixed Asset Turnover	0.11	0.15	0.08	0.08	0.07	0.11	0.12	0.12	0.13	0.14	0.14
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	9,180	9,090	8,974	9,099	9,149	8,830	8,729	8,561	9,259	9,570	9,378
Invested Capital Turnover	0.08	0.11	0.05	0.06	0.05	0.08	0.09	0.09	0.09	0.09	0.10
Increase / (Decrease) in Invested Capital	-330	-272	-785	-153	-32	-261	-245	-538	110	740	650
Enterprise Value (EV)	11,154	10,616	10,872	11,601	12,395	11,630	12,311	13,126	15,184	14,521	14,966
Market Capitalization	5,810	5,436	5,644	6,482	7,474	6,820	7,459	8,315	10,494	10,037	10,732
Book Value per Share	$15.80	$15.41	$14.93	$15.46	$14.98	$14.59	$14.22	$15.02	$16.32	$16.81	$16.82
Tangible Book Value per Share	$13.02	$12.67	$12.18	$12.72	$12.36	$11.96	$11.62	$12.41	$13.82	$14.42	$14.54
Total Capital	9,180	9,090	8,974	9,099	9,149	8,830	8,729	8,561	9,259	9,570	9,378
Total Debt	5,285	5,287	5,288	5,287	5,291	5,067	5,028	4,661	4,858	4,839	4,446
Total Long-Term Debt	5,267	5,268	5,268	5,267	5,272	5,047	5,008	4,590	4,858	4,839	4,446
Net Debt	5,147	4,986	5,039	4,930	4,733	4,623	4,665	4,621	4,498	4,290	4,042
Capital Expenditures (CapEx)	3.48	9.50	5.34	7.85	10	59	21	35	25	25	35
Net Nonoperating Expense (NNE)	-3.57	1.60	-3.65	-1.07	-3.96	-9.76	1.14	-3.24	-5.73	-5.08	-4.03
Net Nonoperating Obligations (NNO)	5,285	5,287	5,288	5,287	5,291	5,067	5,028	4,661	4,858	4,839	4,446
Total Depreciation and Amortization (D&A)	85	85	78	85	82	79	79	77	78	81	81
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.44	$0.20	$0.15	$0.25	$0.37	$0.24	$0.27	$0.46	$0.43	$0.41	$0.34
Adjusted Weighted Average Basic Shares Outstanding	234.18M	234.27M	234.35M	244.87M	244.99M	245.30M	247.10M	257.84M	269.95M	281.84M	289.40M
Adjusted Diluted Earnings per Share	$0.43	$0.20	$0.15	$0.25	$0.37	$0.23	$0.27	$0.45	$0.42	$0.41	$0.33
Adjusted Weighted Average Diluted Shares Outstanding	234.18M	234.27M	234.35M	244.87M	244.99M	245.30M	247.10M	257.84M	269.95M	281.84M	289.40M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	234.18M	234.27M	234.35M	244.87M	244.99M	245.30M	247.10M	257.84M	269.95M	281.84M	289.40M
Normalized Net Operating Profit after Tax (NOPAT)	112	101	41	70	74	45	79	111	124	114	111
Normalized NOPAT Margin	50.23%	34.02%	25.43%	36.12%	40.48%	25.31%	41.64%	55.81%	55.99%	51.98%	47.17%
Pre Tax Income Margin	45.98%	16.21%	21.75%	32.26%	52.94%	34.56%	37.66%	59.82%	50.36%	54.17%	48.85%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1.76	0.84	0.55	1.06	1.56	0.84	1.26	2.15	2.06	2.07	2.13
NOPAT to Interest Expense	1.74	0.83	0.57	1.03	1.53	0.79	1.22	2.11	2.00	2.02	2.07
EBIT Less CapEx to Interest Expense	1.70	0.68	0.46	0.92	1.39	-0.15	0.89	1.50	1.59	1.61	1.46
NOPAT Less CapEx to Interest Expense	1.68	0.66	0.48	0.89	1.36	-0.21	0.85	1.47	1.53	1.56	1.39
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	154.02%	148.89%	235.01%	261.60%	277.21%	269.40%	241.37%	204.28%	194.82%	171.06%	162.28%
Augmented Payout Ratio	187.38%	181.31%	235.01%	261.60%	277.21%	269.40%	241.37%	204.28%	194.82%	171.06%	162.28%

Key Financial Trends

The financial performance and position of Omega Healthcare Investors (NYSE: OHI) over the past four years reveal several key trends and considerations for investors:

Consistent net income growth: Net income attributable to common shareholders increased from $35.9 million in Q1 2023 to $109 million in Q1 2025, indicating improving profitability over time.
Stable dividend payout: The company has maintained a steady dividend payment of $0.67 per share each quarter, supporting income-focused investors.
Substantial cash from operations: Operating cash flow has generally been strong, with $181.95 million generated in Q1 2025 and previous quarters reflecting consistent positive cash flows, supporting operational sustainability.
Investment in property and equipment: The company continues to invest significant amounts in premises and equipment, showing ongoing growth or maintenance of asset base ($63.3 billion in premises and equipment in Q1 2025, an increase from prior periods).
Reduction in debt: Long-term debt declined from $5.0 billion in Q1 2023 to approximately $4.45 billion by Q1 2025, indicating efforts to strengthen the balance sheet.
Negative net interest income: The company consistently records net interest expense (e.g., -$9.16 million in Q1 2025), reflecting interest costs exceeding related interest income, which may be typical for a REIT with significant debt.
Volatility in impairments and restructuring charges: These non-cash expenses fluctuate considerably by quarter, affecting net income comparability.
Capital gains and other non-interest income contribute significantly: Notably large other non-interest income (e.g., $232 million in Q1 2025) and occasional net realized capital gains indicate diverse income sources.
Provision for credit losses remains material: Recent positive provisions (e.g., $5.09 million in Q1 2025) could signal credit risk in underlying assets.
Negative net change in cash and equivalents in Q1 2025 (-$144.7 million) driven by high financing cash outflows (-$347.7 million), mainly debt repayments and dividends, which may pressure liquidity if not offset by operations or capital raises.

Summary: Omega Healthcare Investors demonstrates strong profitability growth and stable dividend payouts with ongoing asset investments and a reducing debt burden, which bodes well for long-term value. However, investors should note persistent net interest expense, sizeable provisions for credit losses, and occasional significant non-cash charges that introduce earnings volatility. The company's ability to generate consistent operational cash flows supports dividend sustainability but monitoring liquidity amid large financing outflows is prudent.

08/24/25 01:18 AMAI Generated. May Contain Errors.

Frequently Asked Questions About Omega Healthcare Investors' Financials

When does Omega Healthcare Investors' financial year end?

According to the most recent income statement we have on file, Omega Healthcare Investors' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Omega Healthcare Investors' net income changed over the last 9 years?

Over the last 9 years, Omega Healthcare Investors' net income changed from $233.32 million in 2015 to $417.80 million in 2024, a change of 79.1%. Check out Omega Healthcare Investors' forecast to explore projected trends and price targets.

How has Omega Healthcare Investors' revenue changed over the last 9 years?

Over the last 9 years, Omega Healthcare Investors' total revenue changed from $743.62 million in 2015 to $829.67 million in 2024, a change of 11.6%.

How much debt does Omega Healthcare Investors have?

Omega Healthcare Investors' total liabilities were at $5.17 billion at the end of 2024, a 3.5% decrease from 2023, and a 32.9% increase since 2015.

How much cash does Omega Healthcare Investors have?

In the past 9 years, Omega Healthcare Investors' cash and equivalents has ranged from $5.42 million in 2015 to $518.34 million in 2024, and is currently $518.34 million as of their latest financial filing in 2024.

How has Omega Healthcare Investors' book value per share changed over the last 9 years?

Over the last 9 years, Omega Healthcare Investors' book value per share changed from 19.98 in 2015 to 16.81 in 2024, a change of -15.9%.

Related Companies

This page (NYSE:OHI) was last updated on 8/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Omega Healthcare Investors (OHI) Financials

Key Financial Trends

Frequently Asked Questions About Omega Healthcare Investors' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Omega Healthcare Investors (OHI) Financials

Annual Income Statements for Omega Healthcare Investors

Quarterly Income Statements for Omega Healthcare Investors

Annual Cash Flow Statements for Omega Healthcare Investors

Quarterly Cash Flow Statements for Omega Healthcare Investors

Annual Balance Sheets for Omega Healthcare Investors

Quarterly Balance Sheets for Omega Healthcare Investors

Annual Metrics And Ratios for Omega Healthcare Investors

Quarterly Metrics And Ratios for Omega Healthcare Investors

Key Financial Trends

Frequently Asked Questions About Omega Healthcare Investors' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools